These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 37180098)

  • 1. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.
    Zhang W; Zhang K; Liu C; Gao W; Si T; Zou Q; Guo Z; Yang X; Li M; Liu D; Mu H; Li H; Yu H; Xing W
    Front Immunol; 2023; 14():1127349. PubMed ID: 37180098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma.
    Pang B; Zuo B; Huang L; You X; Liu T; Hao J; Yuan C; Yang C; Yee Lau W; Zhang Y
    Int Immunopharmacol; 2024 Aug; 137():112492. PubMed ID: 38906005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
    Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
    BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy.
    Li M; Liao J; Wang L; Lv T; Sun Q; Xu Y; Guo Z; Quan M; Qin H; Yu H; Zhang K; Xing W; Yu H
    Front Immunol; 2024; 15():1303259. PubMed ID: 38660298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
    Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
    Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma.
    Huang Z; Chen T; Li W; Qiu J; Liu S; Wu Z; Li B; Yuan Y; He W
    Clin Exp Med; 2024 Jun; 24(1):138. PubMed ID: 38940944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
    Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic Arterial Infusion Chemotherapy Followed by Lipiodol Infusion for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Single-Center Experience.
    Chen KT; Tsai KF; Leung HWC; Chan ALF; Wang SY; Liang HL; Tang SY; Chou CK; Chen HY; Chan SH; Li MF
    Medicina (Kaunas); 2021 Jul; 57(8):. PubMed ID: 34440985
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
    Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
    World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis.
    Cao YZ; Zheng GL; Zhang TQ; Shao HY; Pan JY; Huang ZL; Zuo MX
    World J Gastroenterol; 2024 Jan; 30(4):318-331. PubMed ID: 38313229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of targeted therapy, immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX), and lipiodol embolization in the treatment of unresectable hepatocarcinoma.
    Lin ZP; Hu XL; Chen D; Zou XG; Zhong H; Xu SX; Chen Y; Li XQ; Zhang J; Huang DB
    J Physiol Pharmacol; 2022 Dec; 73(6):. PubMed ID: 37087567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience.
    Zhao W; Liu C; Wu Y; Yao Z; Dou Q; Li W; Zhao X; Xia N
    Transl Cancer Res; 2024 May; 13(5):2315-2331. PubMed ID: 38881913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
    An C; Fu Y; Li W; Zuo M; Wu P
    Cancer; 2023 Jul; 129(14):2235-2244. PubMed ID: 37029486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
    J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of vascular intervention plus lenvatinib versus vascular intervention alone for hepatocellular carcinoma patients with portal vein tumor thrombus: a retrospective comparative study.
    Tang S; Gao Y; Yan X; Zhi W; Han Y
    Front Oncol; 2024; 14():1431069. PubMed ID: 39035736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas.
    Lin Z; Chen D; Hu X; Huang D; Chen Y; Zhang J; Li X; Zou X
    Am J Cancer Res; 2023; 13(11):5455-5465. PubMed ID: 38058801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.
    Oh MJ; Lee HJ; Lee SH
    Clin Mol Hepatol; 2013 Sep; 19(3):288-99. PubMed ID: 24133667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.